Jacobio Pharmaceuticals Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 17, 2027The maintenance fee for KRAS mutant protein inhibitors (US 11,787,811) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,858,359 | Heterocyclic Ring Derivatives Useful as SHP2 Inhibitors In force · High confidence | In force | High confidence | |
| US 10,988,466 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,466,005 | Tricyclic compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 11,136,320 | Fused ring derivative used as FGFR4 inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 12,233,062 | Heterocyclic derivatives useful as SHP2 inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 11,174,319 | Binding molecule specific for CD73 and use of binding molecule In force · From the USPTO record | In force | From the USPTO record | |
| US 12,281,168 | Binding molecule specific for LIF and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,180,506 | KRAS mutant protein inhibitors In force · High confidence | In force | High confidence | |
| US 11,787,811 | KRAS mutant protein inhibitors In force · High confidence | In force | High confidence | |
| US 11,384,066 | Heterocyclic compounds useful as aurora a selective inhibitors In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 15: 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 1 abandoned · 11 no status recorded